Skip to main
ARCT

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics (ARCT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Arcturus Therapeutics Holdings Inc. has reported promising interim data for its ARCT-810 program, showcasing statistically significant improvements in biomarker measures with a favorable safety profile, which bodes well for its ongoing product development. Management highlighted the potential value of the LUNAR LNP platform and exclusive mRNA purification technology, which could drive advancements in various indications beyond cystic fibrosis. Additionally, the continued engagement from key opinion leaders indicates a sustained interest in the company's pipeline, suggesting the possibility for future breakthroughs despite current limitations in clinical data.

Bears say

Arcturus Therapeutics Holdings Inc. faces a negative outlook primarily due to disappointing interim Phase 2 trial results for its ARCT-032 therapy, which failed to demonstrate a meaningful improvement in lung function measured by FEV1, leading to the exclusion of this asset from valuations. Additionally, the company's decision to delay the U.S. launch and remove the LUNAR-COVID Vaccine Global Profit Share from financial models has resulted in significant downward revisions of price targets by analysts. Key risks that compound this negative outlook encompass potential safety issues, ineffective clinical trial results, delays in timelines, and challenges in sufficiently funding operations.

Arcturus Therapeutics (ARCT) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcturus Therapeutics (ARCT) Forecast

Analysts have given Arcturus Therapeutics (ARCT) a Buy based on their latest research and market trends.

According to 9 analysts, Arcturus Therapeutics (ARCT) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcturus Therapeutics (ARCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.